Table 2.
Patterns of GenoType MTBDRplus in comparison to drug susceptibility testing
| Number of sputum samples (%) | DST |
MTBDRplus assay |
Results | |||
|---|---|---|---|---|---|---|
| RMP | INH | RMP
pattern (rpoB) |
INH pattern |
|||
| katG | inhA | |||||
| 8 (6.7%) | R | R | ΔWT3,4, Mut1 (D516V) | ΔWT, Mut1 (S315T) | ΔWT 2, Mut3B (T8A) | MDR |
| 8 (6.7%) | R | R | ΔWT3,4, Mut1 (D516V) | ΔWT, Mut1 (S315T) | ΔWT 2, Mut3A (T8C) | MDR |
| 5 (4.2%) | R | R | ΔWT3,4, Mut1 (D516V) | ΔWT, Mut1 (S315T) | WT | MDR |
| 1 (0.8%) | R | R | ΔWT2,3,4 | ΔWT, Mut1 (S315T) | WT | MDR |
| 1 (0.8%) | R | R | ΔWT2 | ΔWT, Mut1 (S315T) | ΔWT 2, Mut3A (T8C) | MDR |
| 4 (3.3%) | R | R | ΔWT7, Mut2B (H526D) | ΔWT, Mut1 (S315T) | WT | MDR |
| 1 (0.8%) | S | R | ΔWT7, Mut2B (H526D) | ΔWT, Mut1 (S315T) | WT | MDR |
| 2 (1.7%) | R | R | ΔWT7, Mut2B (H526D) | ΔWT, Mut1 (S315T) | ΔWT 2, Mut3A (T8C) | MDR |
| 6 (5%) | R | R | ΔWT7, Mut2A (H526Y) | ΔWT, Mut1 (S315T) | WT | MDR |
| 1 (0.8%) | S | S | ΔWT7, Mut2A (H526Y) | ΔWT, Mut1 (S315T) | ΔWT 2, Mut3A (T8C) | MDR |
| 3 (2.5%) | R | R | ΔWT7 | ΔWT, Mut1 (S315T) | WT | MDR |
| 11 (9.2%) | R | R | ΔWT7, Mut2A (H526Y) | ΔWT, Mut1 (S315T) | ΔWT 2, Mut3A (T8C) | MDR |
| 2 (1.7%) | R | R | ΔWT7, Mut2A (H526Y) | ΔWT, Mut1 (S315T) | ΔWT 2, Mut3B (T8A) | MDR |
| 4 (3.3%) | R | R | ΔWT8, Mut3 (S53L) | ΔWT, Mut1 (S315T) | WT | MDR |
| 2 (1.7%) | R | R | ΔWT8, Mut3 (S53L) | WT | WT | Rif monoR |
| 1 (0.8%) | S | S | ΔWT8, Mut3 (S53L) | WT | WT | Rif monoR |
| 1 (0.8%) | S | S | ΔWT8, Mut3 (S53L) | ΔWT, Mut1 (S315T) | WT | MDR |
| 2 (1.7%) | R | R | ΔWT8, Mut3 (S53L) | ΔWT, Mut1 (S315T) | WT | MDR |
| 11 (9.2%) | S | S | ΔWT8 | WT | WT | Rif monoR |
| 3 (2.5%) | R | R | ΔWT8 | ΔWT, Mut1 (S315T) | ΔWT 2, Mut3B (T8A) | MDR |
| 1 (0.8%) | R | R | ΔWT8 | ΔWT, Mut1 (S315T) | WT | MDR |
| 1 (0.8%) | R | R | ΔWT8 | WT | ΔWT 1, Mut1 (C15T) | MDR |
| 27 (22.5%) | S | S | WT | WT | WT | Susceptible |
| 9 (7.5%) | S | R | WT | ΔWT, Mut1 (S315T) | WT | Inh monoR |
| 2 (1.7%) | S | R | WT | ΔWT, Mut1 (S315T) | ΔWT 2, Mut3B (T8A) | Inh monoR |
| 2 (1.7%) | S | R | WT | WT | WT | Susceptible |
| 1 (0.8%) | S | R | WT | ΔWT, Mut1 (S315T) | ΔWT 2, Mut3A (T8C) | Inh monoR |
| Δ: Absence of hybridization signal with wild-type probes; WT: wild-type; Mut: mutation; DST: drug susceptibility testing; RMP: rifampin; INH: isoniazid; R: resistant; S: susceptible; MDR: multidrug-resistant; Rif monoR: rifampin monoresistant; Inh monoR: isoniazid monoresistant | ||||||